Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis

Martin Hýža,1,2 Petr &Scaron;ilhán,1,2 Eva Če&scaron;ková,1,2 Tomá&scaron; Skřont,1 Ivana Kacířová,3,4 Romana Uřinovská,3 Milan Grundmann4 1Department of Psychiatry, University Hospital Ostrava, Ostrava, Czech R...

Full description

Bibliographic Details
Main Authors:	Hýža M, Šilhán P, Češková E, Skřont T, Kacířová I, Uřinovská R, Grundmann M
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-04-01
Series:	Neuropsychiatric Disease and Treatment
Subjects:	therapeutic drug monitoring antipsychotics psychotic disorders schizophrenia
Online Access:	https://www.dovepress.com/plasma-levels-of-long-acting-injectable-antipsychotics-in-outpatient-c-peer-reviewed-article-NDT

Similar Items

Therapeutic drug monitoring of atypical antipsychotic drugs
by: Grundmann Milan, et al.
Published: (2014-12-01)

Antipsychotic polypharmacy: Retrospective evaluation of cases with psychotic disorder followed in outpatient clinic (tur)
by: Şahabettin Çetin, et al.
Published: (2021-05-01)

Retrospective analysis of antipsychotic prescription models in correlation with symptoms of residual schizophrenia. Part 1
by: D. N. Safonov
Published: (2020-08-01)

Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review
by: Marius H. Sneller, et al.
Published: (2021-03-01)

Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT
by: Anthony P Morrison, et al.
Published: (2021-01-01)

A cross sectional study of trihexyphenidyl utilization on patient receiving antipsychotic therapy
by: Addiniya Nurul Azmi, et al.
Published: (2016-06-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

Withdrawal related adverse effects of antipsychotic medication in a patient with first-episode schizophrenia
by: Barteček Richard, et al.
Published: (2011-10-01)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)

Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update
by: Balázs, T., et al.
Published: (2022)

A 12-Month Retrospective Analysis of Three Long-Acting Antipsychotic Injections in Patients with Schizophrenia: Comparison of Medication Adherence with Psychiatric Hospitalization Rates, Cost of Services, and Concomitant Medications
by: Chuc, Alan, et al.
Published: (2007)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
by: Sugawara N, et al.
Published: (2019-01-01)

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
by: Ludovic Samalin, et al.
Published: (2016-11-01)

Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression
by: Chekani F, et al.
Published: (2020-01-01)

Evaluation of long acting, oral and combination antipsychotic treatments in patients with psychotic disorder (tur)
by: Yasir Şafak, et al.
Published: (2020-01-01)

Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
by: Antonio Ventriglio, et al.
Published: (2019-01-01)

Demographic and clinical correlates of sexual dysfunction among Nigerian male outpatients on conventional antipsychotic medications
by: Oyekanmi Aina, et al.
Published: (2012-06-01)

Therapeutic monitoring of psychoactive drugs - antidepressants: A review
by: Milan Grundmann, et al.
Published: (2015-03-01)

Models of treatment with antipsychotics of the schizophrenic patients
by: Svjetlana Loga-Zec, et al.
Published: (2005-11-01)

Differences in the Effectiveness of Long-Acting Injection and Orally Administered Antipsychotics in Reducing Rehospitalization among Patients with Schizophrenia Receiving Home Care Services
by: Hsiao-Fen Hsu, et al.
Published: (2019-06-01)

Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia – A 3-year follow-up
by: Chen-Chung Liu, et al.
Published: (2015-06-01)

Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations
by: Orietta Zaniolo, et al.
Published: (2019-02-01)

Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program
by: Carmen Gallastegui, et al.
Published: (2019-11-01)

Polycystic Ovary Syndrome and Psychotic Disorder
by: Larissa Doretto, et al.
Published: (2020-06-01)

Identification of Antipsychotic Side Effects with Glassgow Antipsychotic Side-Effect Scale (GASS)
by: Dita Hasni, et al.
Published: (2020-08-01)

THE ROLE OF ATYPICAL ANTIPSYCHOTIC DECREASING AGGRESIVENESS IN SCHIZOPHRENIA
by: Juvita Novia Anggraini Maria
Published: (2013-03-01)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
by: Pietrini F, et al.
Published: (2019-04-01)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
by: Davide Amato, et al.
Published: (2019-05-01)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
by: Ohnishi T, et al.
Published: (2021-04-01)

Atypical Antipsychotics Induced Metabolic Syndrome
by: Aysegul Demirel, et al.
Published: (2015-03-01)

Off-label antipsychotics prescription to adolescents with acute psychotic episodes does not cause adverse drug reactions
by: D. V. Ivashchenko, et al.
Published: (2021-06-01)

Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2019-10-01)

Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?
by: A. A. Goncharova, et al.
Published: (2020-01-01)

Antipsychotic medication non-adherence among schizophrenia patients in Central Ethiopia
by: Minale Tareke, et al.
Published: (2018-03-01)

Evaluation of naltrexone augmentation to the antipsychotic drugs on positive and negative symptoms of schizophrenia
by: Javad Setareh, et al.
Published: (2008-01-01)

The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study
by: D. V. Ivashchenko, et al.
Published: (2020-10-01)

Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside
by: Mujeeb U. Shad
Published: (2021-06-01)

Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia
by: Kristian S. Hill, et al.
Published: (2009-04-01)

Regional brain metabolism in schizophrenia: The influence of antipsychotics
by: Seethalakshmi R, et al.
Published: (2007-01-01)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
by: Sajatovic M, et al.
Published: (2018-06-01)

Cannot write session to /tmp/vufind_sessions/sess_tb66b4ip03080s47uvbpnupnuu